10.1.3 Drugs that suppress the rheumatic disease process

Homepage

Search the NeLM

Medicines A-Z

Find key information about medicines by name (prototype)

Browse by Categories:

Browse by NeLM area:

BNF Category

536 library items in 10.1.3 Drugs that suppress the rheumatic disease process

Filter results by:

Date Published

NeLM Area

Results filtered by:

Category

10: Musculoskeletal and joint diseases (remove) , 10.1 Drugs used in rheumatic diseases and gout (remove) , 10.1.3 Drugs that suppress the rheumatic disease p (remove)

Sort by: Display summary:

Results 1 - 10 of 536

Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next

1.

Cohort study: Incidence of hospitalised bacterial infection associated with juvenile idiopathic arthritis and its treatment

Source: Arthritis and Rheumatism,
Date published: 14/05/2012

Category:

10.1.3 Drugs that suppress the rheumatic disease process | Adverse Drug Reactions | Bacterial | Rheumatology

NeLM Area:

News

Abstract
2.

Horizon scanning: FDA advisory panel recommends approval of tofacitinib for adult patients with moderately to severely active rheumatoid arthritis

Source: PharmaLive,
Date published: 10/05/2012

Category:

10.1.3 Drugs that suppress the rheumatic disease process | Food &Drug Administration (FDA) | Horizon scanning | Rheumatoid Arthritis

NeLM Area:

News

Link
3.

Horizon scanning: Study suggests subcutaneous formulation of tocilizumab is of comparable efficacy to IV formulation

Source: BioSpace ,
Date published: 04/05/2012

Category:

10.1.3 Drugs that suppress the rheumatic disease process | Drug Administration | Rheumatoid Arthritis

NeLM Area:

News

Link
4.

AWMSG issues Final Appraisal Recommendation on use of adalimumab (Humira®) for active polyarticular juvenile idiopathic arthritis

Source: All Wales Medicines Strategy Group (AWMSG),
Date published: 01/05/2012

Category:

10.1.3 Drugs that suppress the rheumatic disease process | All Wales Medicines Strategy Group (AWMSG) | Paediatrics | Rheumatoid Arthritis

NeLM Area:

Evidence > Drug Specific Reviews

Link
5.

Final draft NICE guidance does not support the use of belimumab for treating SLE

Source: NICE,
Date published: 27/04/2012

Category:

10.1.3 Drugs that suppress the rheumatic disease process | National Institute of Clinical Excellence (NICE) | Systemic Lupus Erythematosus

NeLM Area:

News

Final draft guidance (FAD)

Press release

Previous NeLM report on SMC guidance
6.

Should rheumatology patients on immunosuppressive medications be advised against getting tattoos?

Source: Irish Medical Journal,
Date published: 27/04/2012

Category:

10.1.3 Drugs that suppress the rheumatic disease process

NeLM Area:

Evidence > Medicines Management > References

Full text link
7.

Rituximab vs. second anti-TNF therapy for rheumatoid arthritis patients who have failed first anti-TNF: comparative analysis from BSR Biologics Register

Source: Arthritis Care Res ,
Date published: 26/04/2012

Category:

10.1.3 Drugs that suppress the rheumatic disease process | Rheumatoid Arthritis

NeLM Area:

News

Abstract
8.

Medicines reconciliation in paediatric rheumatology patients

Source: Archives of Disease in Childhood,
Date published: 26/04/2012

Category:

10.1.3 Drugs that suppress the rheumatic disease process | Medicines management | Paediatrics

NeLM Area:

Evidence > Medicines Management > References

Abstract link
9.

Orencia (abatacept) powder for concentrate for solution for infusion - Revised SPC

Source: eMC (electronic Medicines Compendium),
Date published: 25/04/2012

Category:

10.1.3 Drugs that suppress the rheumatic disease process | Product Licence Changes | Rheumatoid Arthritis

NeLM Area:

Other Library Updates > SPC Changes

SPC
10.

RCT: Epidural steroids, etanercept, or saline in subacute sciatica

Source: Ann Intern Med,
Date published: 17/04/2012

Category:

10.1.3 Drugs that suppress the rheumatic disease process | Rheumatology

NeLM Area:

News

Abstract

Results 1 - 10 of 536

Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next